Pfizer and Merck & Co have filed their diabetes drug ertugliflozin in the US and EU, and the companies hope their alliance will make an impact in the crowded diabetes drug market. The drug is an ...

and Pfizer may be entitled to additional milestone payments. Cardiovascular safety and outcomes trials are now required for all new diabetes drugs, and are proving to be the most important ...

Meanwhile, Pfizer has some promising drugs in its research ... of clinical-stage incretin-based and oral-based obesity and diabetes treatments, two of which showed promise in mid-stage testing.

while Ozempic and Mounjaro are approved to treat adults with Type 2 diabetes. Yet to enter the highly lucrative GLP-1 agonist market, though, is Pfizer. And now as the focus turns to weight-loss ...

Rubin also believes Pfizer did not chase the right market. “They did not court the nurses, the certified diabetic educators, who play an even bigger role than physicians in deciding to put ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.